Alogliptin and Dolutegravir Interaction
Drug interaction information between Alogliptin and Dolutegravir.
Alogliptin and Dolutegravir have a documented minor interaction in FDA labeling.
FDA drug labeling documents a minor-severity interaction between Alogliptin and Dolutegravir. Major interactions are generally avoided, moderate ones may need monitoring or a dose adjustment, and minor ones are usually low-risk. This page shows the documented mechanism and guidance. Label-documented interactions are not a complete safety review, so always confirm your own medications with a pharmacist or doctor. Educational information, not medical advice.
How They Interact
Dolutegravir can slow down how quickly the body removes metformin. This can cause metformin to build up in the blood, increasing the risk of side effects.
What To Do
Your doctor may need to monitor you more closely or adjust your medication doses.
FDA Label Information
( 7 ) Drugs that reduce metformin clearance (such as ranolazine, vandetanib, dolutegravir, and cimetidine), may increase the accumulation of metformin. Examples: Ranolazine, vandetanib, dolutegravir, and cimetidine Alcohol Clinical Impact: Alcohol is known to potentiate the effect of metformin on lactate metabolism.
Alogliptin Also Interacts With
- Topiramate moderate
- Zonisamide moderate
- Metformin minor
- Ranolazine minor
- Cimetidine minor
Dolutegravir Also Interacts With
- Dofetilide major
- Empagliflozin moderate
- Empagliflozin/Linagliptin moderate
- Ertugliflozin moderate
- Linagliptin moderate
Frequently Asked Questions
Can I take Alogliptin and Dolutegravir together?
This is a minor interaction. Your doctor may need to monitor you more closely or adjust your medication doses.
How serious is the interaction between Alogliptin and Dolutegravir?
This interaction is classified as "minor" severity by the FDA. Minor interactions are unlikely to cause significant problems but should still be mentioned to your healthcare provider.
Why do Alogliptin and Dolutegravir interact?
Dolutegravir can slow down how quickly the body removes metformin. This can cause metformin to build up in the blood, increasing the risk of side effects.
Understanding the Alogliptin and Dolutegravir Interaction
FDA-approved prescribing information for these two drugs flags their combination as a minor-severity interaction. Alogliptin belongs to the DPP-4 Inhibitor class and Dolutegravir belongs to the Integrase Strand Transfer Inhibitor class - two categories that can collide when co-prescribed. The mechanism described in FDA labeling is: Dolutegravir can slow down how quickly the body removes metformin. Severity tiers matter: major flags generally advise avoidance, moderate flags often require monitoring or dose adjustment, and minor flags may only call for awareness.
Context around a specific patient determines real-world impact. Alogliptin has 7 total documented interactions on file in this dataset, and Dolutegravir has 28. Each additional medication compounds the interaction surface, which is why pharmacists run full-profile checks rather than evaluating one pair at a time. FDA-derived guidance for this pair is: Your doctor may need to monitor you more closely or adjust your medication doses. Timing of doses, renal and hepatic function, age, and other concurrent prescriptions all shape whether a labeled interaction matters clinically.
An interaction flag is not a verdict. A large share of labeled interactions are managed routinely in clinical practice, the fix may be as simple as spacing doses or adding a monitoring test. Others require the prescriber to choose a different medication entirely. This page surfaces FDA-sourced labeling and openFDA data for educational purposes only; it is not medical advice and cannot account for your full clinical picture. Never start, stop, or adjust either Alogliptin or Dolutegravir based on a web page, speak with your prescriber or pharmacist before making any change.
Sources: FDA Drug Labels (SPL) via openFDA (2026). This is for informational purposes only and is not medical advice. Always consult your healthcare provider about drug interactions.
Read our methodology - how this data is sourced, computed, and verified.